PharmaShots | Incisive News in 3 Shots

Subscribe Now

Bipolar Disorders I and II

BioXcel Reports the US FDA's Acceptance of BXCL501's NDA for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II

BioXcel Reports the US FDA's Acceptance of BXCL501's NDA for the Acute Treatment of Agitation Associated with Schizophrenia and Bi...

May 19, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us